Uniphar plc

Uniphar plc functions as a multifaceted healthcare solutions provider with operations spanning the Republic of Ireland, the United Kingdom, and international markets. The company is structured into three distinct divisions. The Commercial & Clinical division delivers outsourced sales, marketing, and comprehensive account management services to pharmaceutical and medical product manufacturers. It also facilitates the distribution and offers support services for medical device producers. Through its Product Access division, Uniphar ensures the availability of pharmaco-medical products and treatments by fostering crucial relationships between manufacturers and other healthcare stakeholders. This includes both on-demand access solutions and bespoke distribution partnerships for key pharmaceutical brands. The Supply Chain & Retail division is responsible for the pre-wholesale and wholesale distribution of pharmaceutical, general healthcare, and animal health products to pharmacies, hospitals, and veterinary practices. Furthermore, this division manages a network of retail pharmacies under well-known brands such as Life, Allcare, and Hickey's. Beyond these core areas, Uniphar provides an extensive portfolio of specialized services, encompassing pharmacy support, pharmaceutical supply chain management, expert nursing and infusion services, medical device logistics, healthcare technology integration, data intelligence and consulting, pharmaceutical advisory, medical affairs support, online pharmacy solutions, product fostering, and advanced data solutions tailored for the pharmaceutical industry. Founded in 1967, Uniphar plc maintains its headquarters in Dublin, Ireland.

Uniphar plc trades as UPR.L on LSE. The company is classified in Healthcare / Medical - Distribution and reports in GBP.

The current profile places the business in Medical - Distribution. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £3.07B of revenue and £51.07M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Uniphar plc can be compared against peers such as Allergy Therapeutics plc, Advanced Medical Solutions Group plc, AOTI, Inc., Avon Technologies PLC, Craneware plc, Kooth plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £1.07B, beta of 1.11, and return on equity of +12.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

UPR.L currently shows total debt of £647.77M and beta of 1.11. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.uniphar.ie

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.